Enrolling by invitationPHASE2, PHASE3NCT05929807
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
Studying Achondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ascendis Pharma Growth Disorders A/S
- Principal Investigator
- Claus StrangeAscendis Pharma A/S
- Intervention
- TransCon CNP(drug)
- Enrollment
- 140 enrolled
- Eligibility
- 3-15 years · All sexes
- Timeline
- 2023 – 2039
Study locations (17)
- Ascendis Pharma Investigational Site, Little Rock, Arkansas, United States
- Ascendis Investigational Site, Aurora, Colorado, United States
- Ascendis Investigational Site, Wilmington, Delaware, United States
- Ascendis Investigational Site, Saint Paul, Minnesota, United States
- Ascendis Pharma Investigational Site, Columbia Falls, Montana, United States
- Ascendis Pharma Investigational Site, Buffalo, New York, United States
- Ascendis Investigational Site, Houston, Texas, United States
- Ascendis Pharma Investigational Site, Madison, Wisconsin, United States
- Ascendis Pharma Investigational Site, Parkville, Victoria, Australia
- Ascendis Investigational Site, Linz, Austria
- Ascendis Investigational Site, Montreal, Canada
- Ascendis Pharma Investigational Site, Copenhagen, Denmark
- Ascendis Investigational Site, Berlin, Germany
- Ascendis Pharma Investigational Site, Dublin, Ireland
- Ascendis Investigational Site, Auckland, New Zealand
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05929807 on ClinicalTrials.govOther trials for Achondroplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07388966Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal DysplasiaSYSNAV
- RECRUITINGPHASE2, PHASE3NCT07441876A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaBioMarin Pharmaceutical
- RECRUITINGPHASE2NCT07169279Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company
- RECRUITINGNCT07301463A Study in Children With AchondroplasiaAbbisko Therapeutics Co, Ltd
- RECRUITINGPHASE2NCT06842355A Study of TYRA-300 in Children With Achondroplasia: BEACH301Tyra Biosciences, Inc
- RECRUITINGPHASE2NCT06732895A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Ascendis Pharma A/S
- RECRUITINGPHASE3NCT06926491Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）Kyowa Kirin Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE2NCT06433557A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaAscendis Pharma Growth Disorders A/S